KLK3 and posterior cortical atrophy: The NCCN Clinical Practice Guidelines in Oncology (NCCN guidelines) classify PCa into very low-, low-, favorable/unfavorable intermediate-, high-, and very high-risk categories based on clinical stage, grade group (GG), prostate-specific antigen (PSA) levels, PSA density (PSAD), number of positive cores at biopsy, and occupancy rates [1].